GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of hepatic fat — 19 things I got wrong before I got it right — 48 comments in the full submission. View in context.
1.2k
c/survodutide·submitted 1 year ago by u/cato_girard

hepatic fat — 19 things I got wrong before I got it right

Trial Databranch of 8 comments

Posting this as a discussion rather than a claim: hepatic fat — 19 things I got wrong before I got it right. Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it. Assumed the weight numbers were the point and was corrected. They are secondary to…

Read the full submission and all 48 comments →

This branch

8 comments, started 1 year ago
u/tomas_lokken38 points·1 year ago

independent testing on this compound is very thin

replysharereportpermalink
u/cato_girardOP21 points·1 year ago

Spent an evening on the histology scoring system and understood the trial literature far better afterwards.

replysharereportpermalink
u/border_paperwork12 points·1 year ago

the weight numbers are secondary to what this is being developed for

replysharereportpermalink
[deleted]15 points·1 year ago

[deleted]

replysharereportpermalink
u/slow_logbook_notes3055 points·1 year ago

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

replysharereportpermalink
u/runa_pires27 points·1 year ago

this board is small because the compound is early

replysharereportpermalink
u/tuva_kirchner21 points·1 year ago

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.

replysharereportpermalink
u/elin_ferrari10 points·1 year ago

Nothing containing this compound is approved anywhere.

This is the framing the board needs. It is a hepatic programme first.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.